Association between Class III Obesity (BMI of 40–59 kg/m) and Mortality: A Pooled Analysis of 20 Prospective Studies

English version České info

Background:
The prevalence of class III obesity (body mass index [BMI]≥40 kg/m²) has increased dramatically in several countries and currently affects 6% of adults in the US, with uncertain impact on the risks of illness and death. Using data from a large pooled study, we evaluated the risk of death, overall and due to a wide range of causes, and years of life expectancy lost associated with class III obesity.

Methods and Findings:
In a pooled analysis of 20 prospective studies from the United States, Sweden, and Australia, we estimated sex- and age-adjusted total and cause-specific mortality rates (deaths per 100,000 persons per year) and multivariable-adjusted hazard ratios for adults, aged 19–83 y at baseline, classified as obese class III (BMI 40.0–59.9 kg/m²) compared with those classified as normal weight (BMI 18.5–24.9 kg/m²). Participants reporting ever smoking cigarettes or a history of chronic disease (heart disease, cancer, stroke, or emphysema) on baseline questionnaires were excluded. Among 9,564 class III obesity participants, mortality rates were 856.0 in men and 663.0 in women during the study period (1976–2009). Among 304,011 normal-weight participants, rates were 346.7 and 280.5 in men and women, respectively. Deaths from heart disease contributed largely to the excess rates in the class III obesity group (rate differences = 238.9 and 132.8 in men and women, respectively), followed by deaths from cancer (rate differences = 36.7 and 62.3 in men and women, respectively) and diabetes (rate differences = 51.2 and 29.2 in men and women, respectively). Within the class III obesity range, multivariable-adjusted hazard ratios for total deaths and deaths due to heart disease, cancer, diabetes, nephritis/nephrotic syndrome/nephrosis, chronic lower respiratory disease, and influenza/pneumonia increased with increasing BMI. Compared with normal-weight BMI, a BMI of 40–44.9, 45–49.9, 50–54.9, and 55–59.9 kg/m² was associated with an estimated 6.5 (95% CI: 5.7–7.3), 8.9 (95% CI: 7.4–10.4), 9.8 (95% CI: 7.4–12.2), and 13.7 (95% CI: 10.5–16.9) y of life lost. A limitation was that BMI was mainly ascertained by self-report.

Conclusions:
Class III obesity is associated with substantially elevated rates of total mortality, with most of the excess deaths due to heart disease, cancer, and diabetes, and major reductions in life expectancy compared with normal weight.

Please see later in the article for the Editors' Summary

Vyšlo v časopise: Association between Class III Obesity (BMI of 40–59 kg/m) and Mortality: A Pooled Analysis of 20 Prospective Studies. PLoS Med 11(7): e32767. doi:10.1371/journal.pmed.1001673
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001673

Souhrn

Zdroje

1. World Health Organization (2003) Controlling the global obesity epidemic. Available: http://www.who.int/nutrition/topics/obesity/en/. Accessed 3 June 2014.

2. Prospective Studies Collaboration (2009) WhitlockG, LewingtonS, SherlikerP, ClarkeR, et al. (2009) Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 373: 1083–1096.

3. Berrington de GonzalezA, HartgeP, CerhanJR, et al. (2010) Body-mass index and mortality among 1.46 million white adults. N Engl J Med 363: 2211–2219.

4. PoirierP, CornierMA, MazzoneT, StilesS, CummingsS, et al. (2011) Bariatric surgery and cardiovascular risk factors: a scientific statement from the American Heart Association. Circulation 123: 1683–1701.

5. PascoJA, BrennanSL, KotowiczMA (2013) Morbid obesity in women on the rise: an observational, population-based study. BMC Public Health 13: 290.

6. KortelainenML, PorvariK (2011) Extreme obesity and associated cardiovascular disease verified at autopsy. Am J Forensic Med Pathol 32: 372–377.

7. Health and Social Care Information Centre (2011) Health survey for England—2010, trend tables. Available: http://www.ic.nhs.uk/pubs/hse10trends. Accessed 3 June 2014.

8. SturmR, HattoriA (2013) Morbid obesity rates continue to rise rapidly in the United States. Int J Obes (Lond) 37: 889–891.

9. FlegalKM, CarrollMD, KitBK, OgdenCL (2012) Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA 307: 491–497.

10. ArterburnDE, MaciejewskiML, TsevatJ (2005) Impact of morbid obesity on medical expenditures in adults. Int J Obes (Lond) 29: 334–339.

11. McTigueK, LarsonJC, ValoskiA, BurkeG, KotchenJ, et al. (2006) Mortality and cardiac and vascular outcomes in extremely obese women. JAMA 296: 79–86.

12. BeesonWL, MillsPK, PhillipsRL, AndressM, FraserGE (1989) Chronic disease among Seventh-day Adventists, a low-risk group: rationale, methodology, and description of the population. Cancer 64: 570–581.

13. AlavanjaMC, SandlerDP, McMasterSB, ZahmSH, McDonnellCJ, et al. (1996) The Agricultural Health Study. Environ Health Perspect 104: 362–369.

14. SchairerC, ByrneC, KeylPM, BrintonLA, SturgeonSR, et al. (1994) Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control 5: 491–500.

15. BernsteinL, AllenM, Anton-CulverH, DeapenD, Horn-RossPL, et al. (2002) High breast cancer incidence rates among California teachers: results from the California Teachers Study (United States). Cancer Causes Control 13: 625–635.

16. CalleE, RodriguezC, JacobsEJ, AlmonML, ChaoA, et al. (2002) The American Cancer Society Cancer Prevention Study II Nutrition Cohort—rationale, study design and baseline characteristics. Cancer 94: 2490–2501.

17. ComstockGW, AlbergAJ, HuangHY, WuK, BurkeAE, et al. (1997) The risk of developing lung cancer associated with antioxidants in the blood: ascorbic acid, carotenoids, alpha-tocopherol, selenium, and total peroxyl radical absorbing capacity. Cancer Epidemiol Biomarkers Prev 6: 907–916.

18. OrsiniN, BelloccoR, BottaiM, PaganoM, MichaelssonK, et al. (2008) Combined effects of obesity and physical activity in predicting mortality among men. J Intern Med 264: 442–451.

19. BaikI, AscherioA, RimmEB, GiovannucciE, SpiegelmanD, et al. (2000) Adiposity and mortality in men. Am J Epidemiol 152: 264–271.

20. FolsomAR, KayeSA, SellersTA, HongCP, CerhanJR, et al. (1993) Body fat distribution and 5-year risk of death in older women. JAMA 269: 483–487.

21. GilesGG, EnglishDR (2002) The Melbourne Collaborative Cohort Study. IARC Sci Publ 156: 69–70.

22. TonioloPG, LevitzM, Zeleniuch-JacquotteA, BanerjeeS, KoenigKL, et al. (1995) A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 87: 190–197.

23. SchatzkinA, SubarAF, ThompsonFE, HarlanLC, TangreaJ, et al. (2001) Design and serendipity in establishing a large cohort with wide dietary intake distributions: the National Institutes of Health-American Association of Retired Persons Diet and Health Study. Am J Epidemiol 154: 1119–1125.

24. HuFB, WillettWC, LiT, StampferMJ, ColditzGA, et al. (2004) Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med 351: 2694–2703.

25. ChristenWG, GazianoJM, HennekensCH (2000) Design of Physicians' Health Study II—a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. Ann Epidemiol 10: 125–134.

26. HayesRB, RedingD, KoppW, SubarAF, BhatN, et al. (2000) Etiologic and early marker studies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 21: 349S–355S.

27. WolkA, LarssonSC, JohanssonJE, EkmanP (2006) Long-term fatty fish consumption and renal cell carcinoma incidence in women. JAMA 296: 1371–1376.

28. WeiderpassE, BraatenT, MagnussonC, KumleM, VainioH, et al. (2004) A prospective study of body size in different periods of life and risk of premenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 13: 1121–1127.

29. FreedmanDM, RonE, Ballard-BarbashR, DoodyMM, LinetMS (2006) Body mass index and all-cause mortality in a nationwide US cohort. Int J Obes (Lond) 30: 822–829.

30. WhiteE, PattersonRE, KristalAR, ThornquistM, KingI, et al. (2004) VITamins and Lifestyle cohort study: study design and characteristics of supplement users. Am J Epidemiol 159: 83–93.

31. RexrodeKM, LeeIM, CookNR, HennekensCH, BuringJE (2000) Baseline characteristics of participants in the Women's Health Study. J Womens Health Gend Based Med 9: 19–27.

32. Surveillance Epidemiology, and End Results Program (2012) SEER cause of death recode 1969+ (04/16/2012). Available: http://seer.cancer.gov/codrecode/1969+_d04162012/index.html. Accessed 3 June 2014.

33. World Health Organization (1967) International classification of diseases, 1965 revision (ICD-8). Geneva: World Health Organization.

34. World Health Organization (1977) International classification of diseases, 1975 revision (ICD-9). Geneva: World Health Organization.

35. World Health Organization (2010) International statistical classification of diseases and health related problems, tenth revision. Geneva: World Health Organization.

36. MiniñoAM, AriasE, KochanekKD, MurphySL, SmithBL (2002) Deaths: final data for 2000. Natl Vital Stat Rep 50: 1–119.

37. CurtinLR, KleinRJ (1995) Direct standardization (age-adjusted death rates). Healthy People 2000 Stat Notes 6: 1–10.

38. GhaliWA, QuanH, BrantR, van MelleG, NorrisCM, et al. (2001) Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models. JAMA 286: 1494–1497.

39. MakuchRW (1982) Adjusted survival curve estimation using covariates. J Chronic Dis 35: 437–443.

40. Huedo-MedinaTB, Sánchez-MecaJ, Marín-MartínezF, BotellaJ (2006) Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods 11: 193–206.

41. ThorlundK, ImbergerG, JohnstonBC, WalshM, AwadT, et al. (2012) Evolution of heterogeneity (I2) estimates and their 95% confidence intervals in large meta-analyses. PLoS ONE 7: e39471.

42. NikolopoulouA, KadoglouNP (2012) Obesity and metabolic syndrome as related to cardiovascular disease. Expert Rev Cardiovasc Ther 10: 933–939.

43. CottamDR, MattarSG, Barinas-MitchellE, EidG, KullerL, et al. (2004) The chronic inflammatory hypothesis for the morbidity associated with morbid obesity: implications and effects of weight loss. Obes Surg 14: 589–600.

44. VinciguerraF, BarattaR, Grazia FarinaM, PadovaG, VigneriR, et al. (2013) Very severely obese patients have a high prevalence of type 2 diabetes mellitus and cardiovascular disease. Acta Diabetol 50: 443–449.

45. Maric-BilkanC (2013) Obesity and diabetic kidney disease. Med Clin North Am 97: 59–74.

46. HofsøD, NordstrandN, JohnsonLK, KarlsenTI, HagerH, et al. (2010) Obesity-related cardiovascular risk factors after weight loss: a clinical trial comparing gastric bypass surgery and intensive lifestyle intervention. Eur J Endocrinol 163: 735–745.

47. GoodpasterBH, DelanyJP, OttoAD, KullerL, VockleyJ, et al. (2010) Effects of diet and physical activity interventions on weight loss and cardiometabolic risk factors in severely obese adults: a randomized trial. JAMA 304: 1795–1802.

48. RyanDH, JohnsonWD, MyersVH, PratherTL, McGloneMM, et al. (2010) Nonsurgical weight loss for extreme obesity in primary care settings: results of the Louisiana Obese Subjects Study. Arch Intern Med 170: 146–154.

49. UnickJL, BeaversD, JakicicJM, KitabchiAE, KnowlerWC, et al. (2011) Effectiveness of lifestyle interventions for individuals with severe obesity and type 2 diabetes: results from the Look AHEAD trial. Diabetes Care 34: 2152–2157.

50. JordanJGJr, MannJR (2010) Obesity and mortality in persons with obstructive lung disease using data from the NHANES III. South Med J 103: 323–330.

51. SpencerEA, ApplebyPN, DaveyGK, KeyTJ (2002) Validity of self-reported height and weight in 4808 EPIC-Oxford participants. Public Health Nutr 5: 561–565.

52. McAdamsMA, Van DamRM, HuFB (2007) Comparison of self-reported and measured BMI as correlates of disease markers in US adults. Obesity (Silver Spring) 15: 188–196.

53. ShieldsM, GorberSC, TremblayMS (2008) Effects of measurement on obesity and morbidity. Health Rep 19: 77–84.

54. PrenticeAM, JebbSA (2001) Beyond body mass index. Obes Rev 2: 141–147.

55. SunQ, van DamRM, SpiegelmanD, HeymsfieldSB, WillettWC, et al. (2010) Comparison of dual-energy x-ray absorptiometric and anthropometric measures of adiposity in relation to adiposity-related biologic factors. Am J Epidemiol 172: 1442–1454.

56. HamdyO, PorramatikulS, Al-OzairiE (2006) Metabolic obesity: the paradox between visceral and subcutaneous fat. Curr Diabetes Rev 2: 367–373.

57. PischonT, BoeingH, HoffmannK, BergmannM, SchulzeMB, et al. (2008) General and abdominal adiposity and risk of death in Europe. N Engl J Med 359: 2105–2120.

58. CerhanJR, MooreSC, JacobsEJ, KitaharaCM, RosenbergPS, et al. (2014) A pooled analysis of waist circumference and mortality in 650,000 adults. Mayo Clin Proc 89: 335–345.

59. Al-SamarraiT, MadsenA, ZimmermanR, MaduroG, LiW, et al. (2013) Impact of a hospital-level intervention to reduce heart disease overreporting on leading causes of death. Prev Chronic Dis 10: E77.